Researchers identify new way to reduce chronic nerve pain
Study reveals the BRAF protein, commonly linked to cancer, may also drive chronic nerve pain
After nerve injury, BRAF triggers changes that increase and maintain pain signaling in the spinal cord
Blocking BRAF reduced pain sensitivity in preclinical models
Findings suggest that existing BRAF inhibitors could be used as treatments for pain after nerve injury
Researchers at The University of Texas MD Anderson Cancer Center found new evidence...
First-in-class therapy targets “undruggable” protein in hard-to-treat blood cancers
The MYC protein is involved in about 70% of cancers, but scientists have been unable to develop drugs that effectively block it
Colorectal cancer may quietly damage nerves prior to chemotherapy
Researchers at The University of Texas MD Anderson Cancer Center found that, in preclinical models of colorectal cancer, tumors can start...
Hodgkin lymphoma survivors face twice the risk of death compared to average American adult
Adults who survive Hodgkin lymphoma (HL) for at least five years face increased risk of death from non-cancer conditions and cardiovascular disease
Study reveals need for lifelong survivorship care for patients with HL
Adults who have survived Hodgkin lymphoma (HL) for at least five years face significantly elevated long-term health risks, according to a new study led by researchers at The University of Texas...
Biomarkers may help identify lung cancer patients who benefit most from perioperative immunotherapy
Phase 3 CheckMate 77T trial demonstrated improved outcomes from immunotherapy given before and after surgery, called perioperative immunotherapy...
Scientists uncover drivers of recurrent arthritis after immunotherapy, suggesting potential biomarkers
Some patients receiving immunotherapy can develop recurrent inflammatory arthritis that often worsens in subsequent flare-ups
Researchers...
Immune cell dysfunction, not absence, defines skin cancer in immunosuppressed patients
Patients with weakened immune systems develop non-melanoma skin cancers that are more frequent, more aggressive, and more often lethal ...